← Oncology Approval Tracker

FDA DECISION ·

Veppanu

vepdegestrant · Arvinas Operations

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with ER-positive, HER2-negative advanced or metastatic breast cancer and an ESR1 mutation detected by an FDA-authorized test, after progression on at least one endocrine therapy line.

LAMPGEN ANALYSIS

Why it matters

This brings an estrogen receptor-targeting protein degrader into ESR1-mutated breast cancer after endocrine progression. VERITAC-2 included a biomarker-defined subgroup within a broader enrolled population.

What research teams should watch

Record the molecular result, preceding endocrine regimen and progression date. Keep the approved subgroup visible when translating trial data into screening criteria.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

ESR1-selected advanced or metastatic disease

PRIMARY RECORDS

Sources